SGS has collaborated with Bavarian Nordic to develop a novel and differentiated challenge model for respiratory syncytial virus. This partnership brings both expertise and a view of wanting to bring a life changing therapy to the market. This new model will assist with the advancement of a univeOriginal Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.